Special Issue

Personalized Therapeutics and Drug Development of Liver Disease

Message from the Guest Editors

As , I am pleased to invite submissions to our Special Issue on "Personalized Therapeutics and Drug Development of Liver Disease." This Special Issue seeks to explore the cutting-edge advancements in personalized medicine and drug development specifically tailored to liver diseases, including non-alcoholic fatty liver disease (NAFLD), metabolic dysfunction-associated steatotic liver disease (MASLD), viral hepatitis, liver fibrosis, and hepatocellular carcinoma (HCC). We welcome original research articles, reviews, and other types that contribute to the growing body of knowledge in this dynamic field. Submissions should emphasize the translational aspect of research, bridging the gap between bench and bedside, to offer new hope for patients suffering from liver diseases. We look forward to your contributions that will shape the future of personalized medicine in hepatology.

Guest Editors

Dr. Cristina Muzica

1. Department of Gastroenterology, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania
2. Institute of Gastroenterology and Hepatology, "St. Spiridon" Emergency University Hospital, 700111 Iasi, Romania

Dr. Irina Girleanu

1. Department of Gastroenterology, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania
2. Institute of Gastroenterology and Hepatology, "St. Spiridon" Emergency University Hospital, 700111 Iasi, Romania

Deadline for manuscript submissions

closed (20 May 2025)

MDPI

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker
Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:
indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:
CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).